Inclusion Criteria:  Patients voluntarily signed informed consent; Age 18-75, male or female; Patients diagnosed with solid tumors confirmed by histopathology or cytology; At least one measurable solid lesion has been examined by 18F-FDG PET/CT (RECIST1.1 standard); Patients with biopsy-proven PD-L1 positive; ECOG score ≤ 0~1; Life expectancy of at least 3 months; Women of childbearing age are required to receive serum pregnancy tests, and only those who have a negative pregnancy test for eligible subjects.  Exclusion Criteria:  Currently or within the first 28 days before the first dose to participate in another therapeutic clinical trial. If participating in a non-interventional clinical trial, it is not be excluded; Patients with systemic or locally severe infections (CTCAE ≥ 2); Patients with allergies or allergies to any component of the imaging agent or antibody; Patients who cannot undergo PET/CT imaging; Intolerance of intravenous administration, as well as difficulties in venous blood collection (If having the medical history of fainting during acupuncture, and blood phobia); Symptomatic congestive heart failure (NYHA class II-IV) or symptomatic or poorly controlled arrhythmia; Patients have significant QT/QTC interval prolongation during the screening period; Received anti-tumor therapy (including but not limited to chemotherapy, radiotherapy, biological therapy) within 4 weeks prior to first dose; Patents have not recovered to CTCAE grade 0 or 1 from the adverse events due to cancer therapeutics administered; Patients need to receive other anti-tumor treatments during the trial period； Previously received CD137 agonist or immune checkpoint blocking therapy; Patients with diabetes who have a fasting blood glucose greater than 10 mmol/L; HIV antibody positive, active hepatitis B/C, and TB positive; Patients are regular users (including "recreational use") of any illicit drugs or had a recent history (within the last year) of substance abuse (including alcohol); Patients with symptomatic ascites, pleural effusion, or hydropericardium; Pregnant or lactating women, or planning to become pregnant or have children during this trial.